Precision BioSciences Inc (DTIL)

Precision BioSciences Inc (DTIL) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $173M; returns 1 day -2.1%, 1 week +15.1%, 1 year -4.2%.

Precision BioSciences, Inc. (DTIL) is a clinical-stage gene editing company focused on developing in vivo gene editing therapies using its proprietary ARCUS platform. The ARCUS platform is used for gene insertion, excision, and elimination. The company's two lead programs are PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy.

Groups DTIL belongs to

• Biotechnology
• Gene Therapy
• Clinical Stage Biotech
• Precision Medicine
• Clinical Stage
• Healthcare
• Life Sciences

DTIL financial model: income statement, cash flow and balance sheet